

## 研究成果の刊行に関する一覧表レイアウト

## 雑誌

発表者氏名	論文タイトル名	発表誌名	出版年	巻号	ページ
Takeshi Okuda, Hidetoshi Hayashi, Mitsugu Fujita, Hiromasa Yoshioka, Takayuki Tasaki, <u>Kazuhiko Nakagawa</u> , Amami Kato	Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis.	Int Canc Conf J.	2014		in press
Yang JC, Wu YL, Chan V, Kurnianda J, <u>Nakagawa K</u> , Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS.	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).	Lung Cancer.	2013	S0169-5002 (13)	00535-00537
<u>Okamoto I</u> , Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, <u>Nakagawa K</u> , Tamura T.	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemonaïve patients with advanced nonsquamous non-small-cell lung cancer.	Invest New Drugs.	2013	31(5)	1275-1282
Shaw AT, Kim DW, <u>Nakagawa K</u> , Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.	N Engl J Med.	2013	368(25)	2385-2394
Matsuoka H, <u>Kurata T</u> , <u>Okamoto I</u> , <u>Kaneda H</u> , <u>Tanaka K</u> , <u>Nakagawa K</u> .	Clinical Response to Crizotinib Retreatment After Acquisition of Drug Resistance.	J Clin Oncol.	2013	31(19)	e322-323
Seto T, Kiura K, Nishio M, <u>Nakagawa K</u> , Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T.	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.	Lancet Oncol.	2013	14(7)	590-598
Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, <u>Nakagawa K</u> , Mori K, Nukiwa T, Nakanishi Y, Yamamoto N.	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405).	Jpn J Clin Oncol.	2013	43(6)	664-668
Kogure Y, Ando M, Saka H, <u>Chiba Y</u> , Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, <u>Nakagawa K</u> .	Histology and Smoking Status Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L.	J Thorac Oncol.	2013	8(6)	753-758
Kiyota H, <u>Okamoto I</u> , Takeda M, Daga H, Naito T, Miyazaki M, Okada H, Hayashi H, <u>Tanaka K</u> , Terashima M, Azuma K, Murakami H, Takeda K, Yamamoto N, <u>Nakagawa K</u> .	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.	Cancer Chemother Pharmacol.	2013	71(4)	859-865
Hayashi H, <u>Okamoto I</u> , Taguri M, Morita S, <u>Nakagawa K</u> .	Postprogression Survival in Patients With Advanced Non-Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy.	Clin Lung Cancer.	2013	14(3)	261-266